Difference between revisions of "Profiles"
Jump to navigation
Jump to search
m |
m |
||
| Line 28: | Line 28: | ||
* [[Media:DCEMRIProfile v1 6-20111213.pdf|DCE-MRI Quantification 2011-12-13]] (''Public Comment ended Feb 2012'') | * [[Media:DCEMRIProfile v1 6-20111213.pdf|DCE-MRI Quantification 2011-12-13]] (''Public Comment ended Feb 2012'') | ||
| + | |||
==Statements of Endorsement== | ==Statements of Endorsement== | ||
Revision as of 23:16, 23 June 2017
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Stage 3: Technically Confirmed Profiles
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
Link to QIBA Public Comment Form: http://tinyurl.com/y8dy2pc2
- QIBA fMRI Profile 2017-06-19 Public Comment to open on June 19, 2017
- QIBA PET Amyloid Profile 2017-06-15 Public Comment is open until September 15, 2017
- DWI Profile 2017-04-27 Public Comment is open until July 28, 2017
Stage 1: Public Comment closed
- Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016 (Public Comment ended Feb 2017)
- QIBA Profile: QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening, June 1, 2016 (Public Comment ended Sept 2016)
- DCE-MRI Quantification 2011-12-13 (Public Comment ended Feb 2012)
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)